Medpace Holdings raises 2026 revenue forecast after strong Q2 growth and improved backlog metrics
Medpace Holdings reported a 17.2% year-over-year revenue increase to $707.3 million in Q2 2026, driven mainly by small biopharma clients and growth in Metabolic and Oncology sectors. The company’s net book-to-bill ratio improved to 1.13x and backlog ...
